{"id":2049,"name":"Psymed Ventures","slug":"psymed-ventures","website":"https://psymed.ventures/","hqGeo":"New York, NY","stageFocus":["Pre-Seed","Seed"],"sectorTags":[],"excludedSectors":[],"checkSizeMin":250000,"checkSizeMax":2000000,"thesisSummary":"Psymed Ventures invests in companies at the frontier of mental health and neuroscience, with a strong emphasis on psychedelic medicine.","thesisNarrative":null,"logoUrl":null,"aumUsd":30000000,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"AERSKA","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Regenerative medicine for Alzheimer's and beyond","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ALTO NEUROSCIENCE","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Precision psychiatry drug development platform","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ANCILIA","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"CRISPR for live biotherapeutics and bacterial products","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ATAI LIFE SCIENCES","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Neuro drug development platform with 10+ programs","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"BECKLEY PSYTECH","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Drug development platform focused neurological and psychiatric disorders","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"BEXSON BIOMEDICAL","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Novel ketamine formulations for pain management and mental health disorders","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"BLOOM SCIENCE","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Microbiome therapeutics platform for neurological disease","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"BRIGHT MINDS","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Creating the next generation of psychedelics to treat mental health and other CNS disorders","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"DELIX THERAPUTICS","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Non-hallucinogenic versions of psychedelic compounds with favorable safety and efficacy","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"FREEDOM BIOSCIENCES","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Next generation ketamine & psychedelic therapeutics","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"GILGAMESH PHARMACEUTICALS","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Clinical stage neuroscience biotech developing innovative new chemical entities","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"HUMANS ANONYMOUS","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Anonymous audio spaces for mental health","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"IMYOO","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Patient-centric immune biodiscovery platform","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"IRIS MEDICINE","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Small-binding RNA medicine for neurodegenerative diseases","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"JIMINI HEALTH","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"AI-assisted therapy tool for therapists","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"MAYA HEALTH","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Patient management and data intelligence platform for psychedelic therapy","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"MINDSTATE DESIGN LABS","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Next generation psychedelic-inspired therapeutics for mental health conditions","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"MOTIF NEUROTECH","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Minimally invasive bioelectronic solutions for TRD","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"NEURODE","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Non invasive neurostimulation and monitoring platform, starting with ADHD","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"REMEPY","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Hybrid treatments combining traditional drugs with digital therapeutics","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"RESET PHARMA","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Novel psychedelic treatments for patients with life-threatening illnesses","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"SANMAI","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Transcranial focused ultrasound for mental health","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"SCULPTA BIO","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Programmable RNA splicing medicine for complex brain diseases","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"TACTOGEN","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Drug development platform for gentler and safer entactogens","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"TERRAN","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Drug discovery platform for CNS and mental health","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"TRIPP","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"VR/AR platform for meditation and psychedelic-like experiences","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"STEALTH MARKETPLACE","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Marketplace for transformational mental health modalities","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"STEALTH NEUROTECH","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Biohybrid brain-computer interfaces","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"STEALTH BIOTECH","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Virtual organelle ML models","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"STEALTH HEALTHCARE","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Integrated solution for cancer-specific behavioral health","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Delix Therapeutics","companyUrl":null,"stage":null,"sector":"Neuropsychiatry","investmentYear":null,"description":"Non-hallucinogenic versions of psychedelic compounds","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Journey Clinical","companyUrl":null,"stage":null,"sector":"Psychedelic Therapy","investmentYear":null,"description":"Empowering mental health professionals to offer psychedelic-assisted therapy","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"STEALTH NEUROAI","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Brain data to train better AI","amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":6,"partners":[{"id":18711,"name":"Matias Serebrinsky","title":"General Partner","seniority":null,"focusTags":["Mental & brain health","Frontier neurotechnology","Psychedelics","Precision psychiatry"],"linkedinUrl":"https://www.linkedin.com/in/matiasserebrinsky","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":18712,"name":"Greg Kubin","title":"General Partner","seniority":null,"focusTags":["Mental & brain health","Community building","Digital therapeutics","Alternative modalities"],"linkedinUrl":"https://www.linkedin.com/in/gregkubin","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":18713,"name":"Dina Burkitbayeva","title":"General Partner","seniority":null,"focusTags":["Psychedelic medicine therapeutics","Neuropsychiatric drug development","Innovation in mental health treatments"],"linkedinUrl":"https://www.linkedin.com/in/dinaburkitbayeva","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":18714,"name":"Brooks Leitner, MD-PhD","title":"Partner","seniority":null,"focusTags":["Clinical neuroscience","Translational science","Neurobiology","Mental health biotech"],"linkedinUrl":"https://www.linkedin.com/in/brooksleitner","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":18715,"name":"Tim Gardner, PhD","title":"Partner","seniority":null,"focusTags":["Neurotechnology","Bioengineering","Academic-industry translation"],"linkedinUrl":"https://www.linkedin.com/in/timgardnerphd","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":18716,"name":"Negin Mohktari, PhD","title":"Partner","seniority":null,"focusTags":["Biotechnology investment","Therapeutics","Early-stage life sciences"],"linkedinUrl":"https://www.linkedin.com/in/neginmohktari","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":null,"investmentsThisYear":0},"activityItems":[{"kind":"news","title":"Lux Capital’s Shahin Farshchi on Opportunities in Neuro","url":"https://psymedventures.substack.com/p/lux-capitals-shahin-farshchi-on-opportunities","source":"PsyMed Ventures Substack","occurredAt":"2026-11-02T00:00:00.000Z"},{"kind":"news","title":"PsyMed Ventures host Frontiers of Neuro at Deep Tech Week NYC 2026","url":"https://www.deep-tech-week.com/nyc-2026/events/frontiers-of-neuro-with-psymed-ventures","source":"Deep Tech Week","occurredAt":"2026-04-02T00:00:00.000Z"}],"contentUpdatedAt":"2026-11-06T06:55:37.164Z","investorType":"vc","preferredApproach":"cold outreach ok","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":2457,"name":"Equilibrium Ventures","slug":"equilibrium-ventures","logoUrl":null,"website":"https://equilibrium.co/","stageFocus":["Seed"],"sectorTags":["Developer Tools","Healthcare"],"hqGeo":"Portland, OR"},{"id":8445,"name":"Thrive River Partners","slug":"thrive-river-partners","logoUrl":null,"website":"https://www.trivecapital.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":[],"hqGeo":"Portland, OR"},{"id":8299,"name":"Niche Health Ventures","slug":"niche-health-ventures","logoUrl":null,"website":"https://www.createhealth.vc/","stageFocus":["Seed","Pre-Seed"],"sectorTags":["Healthcare"],"hqGeo":"Denver, Colorado"},{"id":9842,"name":"TheraBridge Ventures","slug":"therabridge-ventures","logoUrl":null,"website":"https://therabridge.com/","stageFocus":["Pre-Seed"],"sectorTags":["Healthcare"],"hqGeo":"Boston, MA"},{"id":8757,"name":"HeartMind Ventures","slug":"heartmind-ventures","logoUrl":null,"website":null,"stageFocus":["Pre-Seed","Seed"],"sectorTags":["Healthcare"],"hqGeo":"Boston, MA"},{"id":8732,"name":"Axis Mental Health Ventures","slug":"axis-mental-health-ventures","logoUrl":null,"website":null,"stageFocus":["Seed"],"sectorTags":["AI / ML"],"hqGeo":"San Francisco, CA"}],"featuredIn":[{"slug":"pre-seed","displayName":"Pre-Seed Investors","pageType":"stage"},{"slug":"seed","displayName":"Seed Investors","pageType":"stage"}],"fundraisingResources":[{"slug":"how-many-investors-should-you-pitch","title":"How Many Investors Should You Pitch? The Math Most Founders Get Wrong"},{"slug":"what-vcs-actually-look-for-pitch-deck","title":"What VCs Actually Look for in a Pitch Deck"},{"slug":"find-right-pre-seed-investors-b2b-saas","title":"How to Find the Right Pre-Seed Investors for Your B2B SaaS Startup"}],"overviewNarrative":"Psymed Ventures is a venture capital firm headquartered in New York, NY. The firm invests in companies at the frontier of mental health and neuroscience, with a strong emphasis on psychedelic medicine.\n\nPsymed Ventures focuses on pre-seed and seed stages. It invests in the psychedelics and mental health sectors. Typical check size ranges from $250K to $2.0M. The firm has $30M in assets under management. Cold outreach is an accepted way to approach the firm.","portfolioNarrative":"Psymed Ventures has recorded investments in 33 portfolio companies. These include AERSKA, ALTO NEUROSCIENCE, ANCILIA, ATAI LIFE SCIENCES, BECKLEY PSYTECH, BEXSON BIOMEDICAL, BLOOM SCIENCE, BRIGHT MINDS, Delix Therapeutics, DELIX THERAPUTICS, FREEDOM BIOSCIENCES, GILGAMESH PHARMACEUTICALS, HUMANS ANONYMOUS, IMYOO, and IRIS MEDICINE. One recorded investment is in Delix Therapeutics in the neuropsychiatry sector.\n\nThe firm is backed by a team of partners with expertise in mental and brain health, psychedelic medicine therapeutics, neuropsychiatric drug development, clinical neuroscience, neurotechnology, and biotechnology investment.","seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-06-13T08:11:23.079Z"}